Mount Sinai BioDesign expands collaboration with the MedTech community to advance medical innovation

Mount Sinai Health System today announced that Mount Sinai BioDesign, the health system’s health technology incubator, has expanded its footprint to become a key, effective partner to the broader MedTech community.

Through synergistic partnerships between clinicians, technologists and industry partners, Mount Sinai BioDesign is able to offer a range of services, including expert clinical and engineering opinions, preclinical study development and execution, data collection and analysis, and management of pivotal clinical trials. Mount Sinai BioDesign has already partnered with several mature partnerships that have successfully designed and initiated clinical trials, conducted user research, assisted in U.S. Food and Drug Administration submissions, and facilitated the development of novel algorithms. Mount Sinai BioDesign is now actively seeking to expand its collaborations with a growing number of industry partners.

In recent years, Mount Sini BioDesign has evolved from focusing solely on internal projects to becoming a key resource for industry partners and start-ups. This strategic shift has enabled our team to help third parties navigate the complexities of health systems integration and accelerate the development and adoption of new technologies. By collaborating with key industry leaders, we have been able to extend our impact to broader specialties at various stages of the translational process, while increasing their ability to effectively develop next-generation tools that will help clinicians and improve treatment and patient care.

Benjamin Rapoport, MD, assistant professor of neurosurgery at Icahn Mount Sinai and chief scientific officer of Mount Sinai BioDesign

Through its expansion, Mount Sinai BioDesign is partnering with startups through Elementa Labs, a Mount Sinai virtual accelerator program that enables startups to explore ways to strategically align their efforts with Mount Sinai. Mount Sinai BioDesign is a key program partner in identifying and working with MedTech companies, helping to develop post-program opportunities that benefit both startups and broader Mount Sinai initiatives

Founded in 2017 under the leadership of Dr. Joshua B. Bederson, system chair of the Division of Neurosurgery, Mount Sinai BioDesign combines clinical and engineering expertise to catalyze the translation of innovative ideas into tangible solutions that improve patient outcomes. Initially focused on solving internal clinical challenges, it has since become a cornerstone of medical innovation within the Mount Sinai Health System and has developed a strong track record in project management and commercialization. A multidisciplinary team of physicians, designers, engineers and entrepreneurs have transformed complex medical challenges into opportunities for technological advancement, developing the culture of innovation that is paramount at Mount Sinai.

“Mount Sinai BioDesign creates an environment where novel concepts are transformed into patents, prototypes, and ultimately commercially viable products,” said Dr. Bederson, executive director of Mount Sinai BioDesign and the Leonard I. Malis/Corinne and Joseph Graber Professor of Neurosurgery at Mount Icahn at Sinai. “Each year, we work with dozens of active clinicians and surgeons to guide them through an innovative, phased system of product development and startup launches, and we now have a proven track record of successful projects with health technology collaborators of all sizes. We want to expand our reach even further to offer startups and established industry leaders unprecedented opportunities to advance their products and make their innovations available to the many patients we serve.”